Survival curves showing therapeutic efficacy of 20-2b in disseminated Burkitt lymphoma (Raji and NAMALWA) xenograft models. Female C.B. 17 SCID mice were administered NHL cells intravenously on day 0. (A) Advanced Raji model. Groups of 10 received 250-pmol doses on days 5, 7, 9, 12, 14, and 16. Treatments consisted of 20-2b (●), 734-2b (■), v-mab (○), or saline (X) given as subcutaneous doses. (B) Early NAMALWA model. Groups of 10 received 250-pmol doses on days 1, 3, 5, 8, 10, and 12. Treatments consisted of 20-2b (●), 734-2b (■), v-mab (○), rituximab (□), v-mab plus 734-2b (■), rituximab plus 734-2b (▴), or saline (X) given as subcutaneous doses. Survival curves were analyzed using Prism software.